Navigation Links
Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Announces the Highly Anticipated Release of Medrio 8.1 with iPad Support
Date:4/23/2013

San Francisco, CA (PRWEB) April 23, 2013

Medrio, a leading EDC and eClinical SaaS provider for clinical research, announces the highly anticipated release of Medrio 8.1 with iPad support. In this release, the same powerful platform has been redesigned with a fresh new look and offers customers enhanced navigation for ease of use.

Highlights of the Medrio 8.1 with iPad support release:

  •         Most commonly used functions are more readily available
  •         New workflow-driven home screen with high-level summaries
  •         Enter and monitor data on-site with your iPad
  •         Manage your study remotely

“The new 8.1 Medrio user interface was thoughtfully designed and helps the user navigate the pages more intuitively,” said Ashleigh Wilson, Clinical Data Manager at Heartflow. “It allows me to find what I need with fewer clicks and less time spent scrolling. The addition of iPad support will help our monitors greatly in the field.”

“We are thrilled to unveil Medrio 8.1, a more user-friendly platform we’ve designed in order to make our system simpler to navigate and perform the tasks necessary to conduct clinical trials,” said Jeff Johnson, Medrio’s Director of Customer Experience. “We’ve also incorporated features to improve system performance and maintain our high level of reliability. This has been a collaborative effort and our customers are responding with a great deal of excitement about the new platform and superior usability.”

About Medrio, Inc.

Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in the San Francisco Bay Area. For more information visit http://www.medrio.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10525701.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
2. Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services
3. Biotrial, a Successful Leading CRO, Continues to Expand its Activities, Creating a Unique Neuroscience Pool of Talent and Capabilities: Biotrial Neuroscience
4. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
5. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
6. Leading Photonics and Laser Researchers to Present Latest Work at SPIE Optics + Optoelectronics
7. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
8. BioElectronics Product Cited for "Most Innovative New OTC Product" From Leading UK-based Healthcare Marketing Publication
9. Dr. Ali S. Faqi and Leading Scientists Author Ground-Breaking Toxicology Book from Elsevier
10. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
11. Mylan to Acquire Agila to Create Leading Global Injectables Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):